Register
Login:
Share:
Email Facebook Twitter


Tech company Mporium delivers an outstanding set of Q1 results says CEO De Groot
IronRidge Resources CEO hails spectacular lithium project and money making potential for gold


ShareCast News


Smith & Nephew drops on NuVasive deal report

Mon, 11th Feb 2019 09:19


(Sharecast News) - Shares in Smith & Nephew fell on Monday following a report that the maker of hip and knee replacement products is in discussions to buy US medical equipment company NuVasive for more than $3bn.

Late on Friday, the Financial Times said the exact terms of any discussions had not been learned and talks between the two parties may fall apart.

Goldman Sachs pointed out that the FT article came just a day after S&N said in its full-year results that it plans to more actively pursue M&A and to increase average leverage to 2.0x-2.5x net debt/EBITDA.

"Notably, Smith & Nephew stated it was looking at potential targets across the entire global Medtech universe, as opposed to solely looking within the company's existing end-markets (hips, knees, trauma, sports medicine, and wound care), with management stressing that strategic fit was the key consideration," GS said.

Goldman took no view on the likelihood of a deal being announced but said an acquisition of NuVasive would expand the scope of S&N's business into the spine market, similar to major orthopaedic peers JNJ, Stryker, and Zimmer Biomet.

"As such, we think any acquisition would be strategically aligned with peers' product strategy," it said.

"That said, an acquisition of NuVasive would likely have only a modest impact on Smith & Nephew's organic revenue growth outlook: we calculate average organic revenue growth of 3.4% per annum (2020-22E) for Smith & Nephew including NuVasive, up from 3.0% for Smith & Nephew on a stand-alone basis.

"More importantly, in our scenario analysis, an acquisition could be 40-230 basis points dilutive to Smith & Nephew's stand-alone CROCI of 11.7% in 2022E, with value creation - i.e., achieving a cash return on capital invested (CROCI) in excess of Smith & Nephew's cost of capital - depending solely on the company realizing cost synergies, which would be subject to execution risks."

The bank also highlighted the potential for integration risks given S&N's lack of exposure to the spine end-market, but acknowledged that the CEO previously headed up the Depuy Synthes spine business at JNJ between 2011 and 2012.

NuVasive makes devices designed to be used in minimally invasive spinal procedures.

Cantor Fitzgerald said it's unlikely that S&N will be NuVasive as there are more attractive acquisition targets that would better align with the goals of the company's renewed M&A focus.

"Specifically, we think there are better potential acquisition targets in end markets adjacent to SNN with faster growth that would better leverage SNN's existing businesses," it said.

It noted that while NuVasive's revenue growth of around 5% in 2018 was slightly faster than S&N's 3% growth, the overall spine market is growing by only 0-2%, below the market growth of S&N's current end markets.

Additionally, NuVasive's gross and operating margins would be dilutive to SNN," it said.

"It is possible that SNN might be compelled to add a spine business because it is the only large orthopedic company - others being Zimmer Biomet, Johnson & Johnson and Stryker - that does not have a spine business. That said, we don't think that would be reason for SNN to make the acquisition."

At 1235 GMT, S&N shares were down 4% to 1,454p.


Related Shares:



Back to ShareCast News


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.